TY - JOUR KW - Adolescent KW - Adult KW - Aging KW - Amides KW - Chemical and Drug Induced Liver Injury KW - Dapsone KW - Drug Therapy, Combination KW - Female KW - Humans KW - leprosy KW - Male KW - Middle Aged KW - Rifampin KW - Sex Factors KW - Thioamides AU - Cartel J L AU - Millan J AU - Guelpa-Lauras C C AU - Grosset J H AB -

A 13% incidence of hepatitis was observed among 54 cases of multibacillary leprosy treated daily with the three-drug combination of dapsone, rifampin, and a thioamide (ethionamide or prothionamide). No hepatitis was observed among 109 cases of paucibacillary leprosy treated daily with the two-drug combination of dapsone and rifampin. Symptoms were jaundice in five cases and nausea plus vomiting associated with a significant increase of transaminase levels in two cases. In five cases, the symptoms appeared during the first two months of therapy and in two cases, later. Discontinuing treatment with rifampin and the thioamide but not dapsone resulted in recovery. When rifampin was resumed without the thioamide, the hepatitis did not recur. Viral etiology could be eliminated in six cases. Neither sex, age, weight nor the fact that the patient was a new case or a relapse case appeared to be a contributing factor. Hepatotoxicity caused by administration of a thioamide might have been potentiated by the concurrent administration of rifampin.

BT - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association C1 -

http://www.ncbi.nlm.nih.gov/pubmed/6686970?dopt=Abstract

DA - 1983 Dec IS - 4 J2 - Int. J. Lepr. Other Mycobact. Dis. LA - eng N2 -

A 13% incidence of hepatitis was observed among 54 cases of multibacillary leprosy treated daily with the three-drug combination of dapsone, rifampin, and a thioamide (ethionamide or prothionamide). No hepatitis was observed among 109 cases of paucibacillary leprosy treated daily with the two-drug combination of dapsone and rifampin. Symptoms were jaundice in five cases and nausea plus vomiting associated with a significant increase of transaminase levels in two cases. In five cases, the symptoms appeared during the first two months of therapy and in two cases, later. Discontinuing treatment with rifampin and the thioamide but not dapsone resulted in recovery. When rifampin was resumed without the thioamide, the hepatitis did not recur. Viral etiology could be eliminated in six cases. Neither sex, age, weight nor the fact that the patient was a new case or a relapse case appeared to be a contributing factor. Hepatotoxicity caused by administration of a thioamide might have been potentiated by the concurrent administration of rifampin.

PY - 1983 SP - 461 EP - 5 T2 - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association TI - Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. UR - http://ila.ilsl.br/pdfs/v51n4a01.pdf VL - 51 SN - 0148-916X ER -